Stevanato Group (STVN) The 44th Annual William Blair Growth Stock Conference summary

Company overview and market position

• Plays a mission-critical role in biopharmaceutical and diagnostic industries, serving over 700 global customers.

• Achieved steady double-digit revenue and margin growth, closing 2023 with €1,085 million revenue and nearly 27% EBITDA margin.

• Holds leading positions in pen cartridges, EZ-fill vials, and glass converting technology.

• Focused exclusively on the pharmaceutical industry for the past 50 years, with proprietary engineering for glass forming.

• Expanded globally with 16 sites in 9 countries, offering consistent quality and security of supply.

Strategic growth and investments

• Accelerated growth through integrated R&D, acquisitions in high-precision molding, and global manufacturing expansion.

• Became public in 2021 to raise capital for high-value product investments.

• Major investments in new facilities in Fishers, Indiana, and capacity expansion in Italy; China facility development is on hold.

• Fishers plant represents the largest investment, nearing €500 million, focused on biologics and high-value solutions.

• Investments are demand-driven, with expected ROI above 20% and multi-year customer contracts.

Product portfolio and customer solutions

• Offers integrated solutions across drug containment, delivery devices, analytical testing, and regulatory support.

• Biopharma diagnostic solutions accounted for 81% of 2023 revenue; engineering segment supports manufacturing and inspection.

• High-value products like Nexa, Alba, and EZ-fill Smart meet stringent biologic requirements.

• Provides tailored solutions from early-stage development to commercial manufacturing, as illustrated by the Merck Serono case study.

• High-value solutions represented over 34% of 2023 revenue and are expected to grow.